reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
PEG-MGF
PEG-MGF is a PEGylated (polyethylene glycol-modified) version of mechano growth factor designed to extend the parent peptide's approximately 5-minute half-life, with no published studies under this compound name.
Evidence landscape: 3 published studies
0 published studies under this compound name.
- 3 Other research
Not FDA-approved. Not in clinical development. No published studies exist under the name PEG-MGF. The entire evidence base is extrapolated from MGF (mechano growth factor) research.
Available through research peptide suppliers. Not available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient. No prescription pathway exists.
PEG-MGF is a PEGylated form of the IGF-1 Ec splice variant. The parent compound MGF is produced by exercising muscle and activates satellite cells. PEGylation is a well-established pharmaceutical modification used across many approved drugs to extend half-life.
PSI Assessment
A PEGylated (polyethylene glycol-modified) version of mechano growth factor designed to extend the peptide's extremely short natural half-life from approximately 5 minutes to a potentially usable duration. The parent compound MGF (mechano growth factor, already on this platform) is a splice variant of IGF-1 (insulin-like growth factor 1) that activates satellite cells in damaged muscle tissue. PEG-MGF attaches a PEG molecule to slow enzymatic degradation. No published studies exist under the name PEG-MGF. The entire evidence base for this compound is extrapolated from MGF research, and whether PEGylation preserves the parent peptide's biological activity has not been established in any published study.
Zero published studies under PEG-MGF. Properties extrapolated from parent MGF research. Whether PEGylation preserves biological activity is unverified.
The theoretical mechanism is identical to MGF (satellite cell activation via the unique C-terminal E domain of the IGF-1 Ec splice variant), with PEGylation extending the half-life by reducing renal clearance and protease degradation. PEGylation is a well-established pharmaceutical modification used across many approved drugs. Whether the PEG molecule interferes with MGF's receptor binding, satellite cell activation, or tissue distribution has not been studied.
What the evidence supports
PEGylation is a well-established pharmaceutical modification that typically extends peptide half-life. The parent compound MGF activates satellite cells through a unique mechanism documented in published research. The structural modification is straightforward.
What is not yet established
Whether PEG-MGF retains the satellite cell activation of the parent MGF compound. Pharmacokinetics, bioavailability, and actual half-life extension of the PEGylated form. Safety profile. Any aspect of efficacy specific to PEG-MGF rather than MGF.
Research Evidence
The findings below are extrapolated from MGF research. No published studies exist under PEG-MGF specifically.
Evidence by condition
Evidence dimensions available for each condition PEG-MGF has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Muscle Repair | ||||
| Satellite Cell Activation | ||||
| Recovery |
PEGylation is a well-established pharmaceutical modification that extends peptide half-life by reducing renal clearance and protease degradation. Multiple FDA-approved drugs use PEGylation. The modification is structurally straightforward.
The PEGylation technology itself is validated. Whether it preserves the specific biological activity of MGF has not been tested in any published study.
How PEG-MGF Works
PEG-MGF is the PEGylated form of the IGF-1 Ec splice variant (mechano growth factor), a 24-amino-acid C-terminal peptide produced by exercising muscle. The PEG attachment is designed to extend the approximately 5-minute biological half-life of unmodified MGF.
A lab-modified version of a natural muscle repair signal designed to last longer in the body.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
PEGylated Ec splice variant of IGF-1 with unique 24-amino acid C-terminal E domain. Activates satellite cell proliferation.
What is PEG-MGF being studied for?
Researchers are studying PEG-MGF across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for PEG-MGF overall. This means a compound can have human studies for one condition but only animal data for another.
Muscle Repair
·PreclinicalThe parent compound MGF activates satellite cells in animal models. Whether PEG-MGF retains this activity is unknown. No published studies test PEG-MGF for muscle repair.
Limitations: Zero published evidence for PEG-MGF specifically. All claims extrapolated from MGF research.
Satellite Cell Activation
·PreclinicalMGF activates satellite cells through a unique mechanism involving the C-terminal E domain of the IGF-1 Ec splice variant. Whether PEGylation preserves this receptor interaction is unstudied.
Limitations: Mechanistic extrapolation only. No PEG-MGF-specific satellite cell data.
Recovery
·PreclinicalGeneral recovery claims are based on the MGF satellite cell activation mechanism. PEG-MGF adds theoretical half-life extension. Neither the recovery application nor the half-life extension has been tested under this compound name.
Limitations: No published data. Entirely theoretical.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. No Investigational New Drug application has been filed. No published studies exist under this compound name.
Availability: Available through research peptide suppliers only. Not available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
Class context: PEGylation is a well-established pharmaceutical modification. The parent compound MGF is a naturally occurring splice variant of IGF-1. IGF-1 pathway stimulation carries theoretical cancer risk.
No human safety data exists for PEG-MGF. The parent compound MGF has limited safety characterization. IGF-1 pathway stimulation carries theoretical cancer risk from promoting cell proliferation.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a PEG-MGF discussion.
Comparison and Related Research
PEG-MGF is positioned within the IGF-1 family and muscle repair peptide space. Understanding the parent compound and alternatives clarifies the evidence gaps.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational study demonstrating that the mechano growth factor (MGF) splice variant of IGF-I plays a distinct role from mature IGF-I in muscle cell biology. MGF promoted proliferation of myoblasts, while mature IGF-I promoted differentiation, suggesting the two peptides serve different functions in muscle repair.Yang SY & Goldspink G, 2002 in FEBS Lett. View on PubMed
- 2.Demonstrated that local tissue damage in rodent muscle triggers IGF-I gene splicing, producing MGF, which was associated with activation of muscle satellite (stem) cells. This provided evidence that MGF serves as an early signal in the muscle repair process.Hill M et al., 2003 in J Physiol. View on PubMed
- 3.Animal study showing that MGF administration reduced the loss of cardiac function following acute myocardial infarction. The findings suggested that MGF may have protective effects on cardiac tissue beyond its established role in skeletal muscle repair.Carpenter V et al., 2008 in Heart Lung Circ. View on PubMed
- 4.Comprehensive review of PEGylation technology, which attaches polyethylene glycol chains to therapeutic peptides and proteins. PEGylation extends the half-life of compounds like MGF by reducing renal clearance and enzymatic degradation, which is the rationale behind the PEG-MGF variant.Jain A et al., 2008 in Crit Rev Ther Drug Carrier Syst. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.